Recent advances in type 2 diabetes (T2D) research have highlighted the benefits of sodium‐
glucose co‐transporter‐2 (SGLT‐2) inhibitors, including cardiovascular and renal protection …

The sodium-glucose transporter 2 inhibitors (SGLT2i) are a relatively new class of
medication used in the management of type 2 diabetes. Recent clinical trials and research …

Abstract Dapagliflozin [Farxiga®(USA); Forxiga®(EU)], a sodium–glucose cotransporter 2
(SGLT2) inhibitor, was recently approved in the USA and the EU for the treatment of adults …

Heart failure (HF) is a worldwide pandemic that affects at least 26 million people and is
becoming more prevalent. Heart failure health expenditures are substantial and will …

It is now well-established that the therapy of type II diabetes mellitus has undergone a
radical change in the past 15 years: countless innovative drugs, such as SGLT2I, able to …

Globally, cardiovascular disease (CVD) and chronic kidney disease (CKD) are the leading
causes of mortality. Despite medical advances, these illnesses are still underdiagnosed and …

Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce new-onset atrial
fibrillation (AF) in patients with type 2 diabetes mellitus (T2DM). We aimed to determine the …

Heart failure (HF) is a clinical syndrome that results from any structural or functional
impairment of ventricular filling or ejection of blood, and results in low life quality and …

Initially intended as an adjunct treatment for type 2 diabetes mellitus (T2DM), SGLT2-
inhibitors (SGLT2i) have transformed into an unexpected pillar of the heart failure (HF) …

Background: The global prevalence of type 2 diabetes mellitus (T2DM) is growing yearly.
The efficacy of ertugliflozin (ERT), a recently licensed anti-diabetic drug, has been widely …